Who makes Discontinuation of β-blocker?

Discontinuation of β-blocker is developed by Samsung Medical Center.

What development phase is Discontinuation of β-blocker in?

Discontinuation of β-blocker is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Discontinuation of β-blocker

Samsung Medical Center · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Discontinuation of β-blocker
Sponsor	Samsung Medical Center
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease (PHASE4)
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC (PHASE1)
Long-term Beta-blocker Therapy After Acute Myocardial Infarction (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Discontinuation of β-blocker CI brief — competitive landscape report
Discontinuation of β-blocker updates RSS · CI watch RSS
Samsung Medical Center portfolio CI